

The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time

Session Title: Resources from the NCI-Sponsored Human Tumor Atlas Network

Sharmistha Ghosh-Janjigian, PhD Program Director Division of Cancer Biology National Cancer Institute (NCI) National Institutes of Health (NIH) Bethesda, Maryland

Disclosure Information



APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25

Sharmistha Ghosh-Janjigian

I have no financial relationships to disclose.

The NCI Human Tumor Atlas Network (HTAN)*




APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25

Overarching program goal: Construct dynamic 2D and 3D atlases of human cancers

- Integrate molecular, cellular, and tumor tissue composition and architecture, including the microenvironment and immune milieu
- Describe *transitions during cancer:* pre-malignant lesions to malignancy, locally invasive to metastatic cancer
- Enable *predictive modeling* to refine detection and therapeutic choices

*HTAN Phase 1: 2018–2024 *HTAN Phase 2: Launched in Fall 2024




HTAN Marker Paper, Cell 2020: https://doi.org/10.1016/j.cell.2020.03.053

Tumor Atlases: Facilitating an Era of Precision Medicine



APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25



HTAN Marker Paper, Cell 2020: https://doi.org/10.1016/j.cell.2020.03.053


HTAN Principles



- Community Resource create a community resource that catalyzes cancer research across disciplines
- Complementary Approaches strengths and weaknesses will be discovered as a Network; expect to work together
- Open Communication accelerate science by breaking down walls; strive towards interoperability
- Data and Resource Sharing requirement for success; expect aggressive public data/resource release timelines

Multimodal and Spatial Atlases





HTAN Phase 1 Tumor Types (2018–2024)

AACR American Association for Cancer Research*

APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25

BREAST

Shelley Hwang, Carlo Maley and Robert West Duke University, Arizona State University and Stanford University

Joe Gray, Gordon Mills, Jeremy Goecks and George Thomas Oregon Health and Science University

Bruce Johnson and Aviv Regev Dana-Farber Cancer Institute and Broad Institute

Li Ding, Ryan Fields, William Gillanders and Samuel Achilefu $\ensuremath{\mathsf{Washington}}$ University in St. Louis

Frederick National Laboratory for Cancer Research (FNLCR) and Broad Institute Tumor Atlas Pilot

MCL Consortium Pre-Cancr Atlas Pilot

SKIN

Peter Sorger, Sandro Santagata an Jon Aster Harvard University and Brigham and Women's Hospital

Bruce Johnson and Aviv Regev Dana-Farber Cancer Institute and Broad Institute

PEDIATRIC

FNLCR and Broad Institute Tumor Atlas Pilot glioma / neuroblastoma / sarcoma

Kai Tan and Stephen Hunger Children's Hospital of Philadelphia

glioma / neuroblastoma / very high risk acute lymphoblastic leukemia





Memorial Sloan Kettering Cancer Center MCL Consortium Pre-Cancr Atlas Pilot Li Ding, Ryan Fields, William Gillanders and Samuel Achilefu

Avrum Spira and Steven Dubinett

of Screen Detected Lesions (MCL) Consortium Pre-Cancr Atlas Pilot

Memorial Sloan Kettering Cancer Center

PANCREAS

Washington University in St. Louis

Boston University and University of California Los Angeles

Molecular and Cellular Characterization

Dana Pe'er and Christine Icabuzio-Donahue

Dana Pe'er and Christine Icabuzio-Donahue

COLON

LUNG

Michael Snyder and James Ford Stanford University

Robert Coffey, Ken Lau and Martha Shrubsole Vanderilt University

Bruce Johnson and Aviv Regev Dana-Farber Cancer Institute and Broad Institute

FNLCR and Broad Institute Tumor Atlas Pilot

HTAN Phase 2 Tumor Types (Launched in Fall 2024)



APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25

PROSTATE

Li Ding, Feng Chen, Eric Kim and Russell Pachynski Washington University in St. Louis

COLON

Ken Lau and Jeffery Spraggins Vanderbilt University

OVARY

Samuel Mok, Michael Birrer and Sammy Ferri-Borgogno MD Anderson

LYMPHOMA Rong Fan, Stephanie Halene, Zongming Ma and Mina Xu Yale University

PEDIATRIC SOLID TUMORS

Rhabdomyosarcoma, Neuroblastoma and Wilms Tumor Shahab Asgharzadeh, James Amatruda and Long Cai University of California, Los Angeles





https://data.humantumoratlas.org/

Dana Farber Cancer Institute

SKIN

Cell Carcinoma

PANCREAS

and Laura Wood

GASTRIC

MD Anderson

Irene Ghobrial

and Paul Mansfield

MYELOMA

BRAIN

Melanoma and Cutaneous Squamous

Rosalie Sears, Elana Fertig, Jonathan Brody

Oregon Health & Science University

Long Cai, Richard Everson, Matthew

California Institute of Technology


Linghua Wang, Tae Hyun Hwang, Mingyao Li

Thomson and Barbara Wold

Alan Shain, Boris Bastian and Iwei Yeh University of California, San Francisco


Interconnectivity Within HTAN HTAN Phase 1 Collaborative Projects





Interconnectivity Across Community






HTAN Data Jamborees



- Virtual HTAN Jamboree, Dec 2023, and In-Person HTAN Jamboree, Nov 2024
 - ~200 total participant applications
 - ~30 total project pitch submissions
- 87 participants were selected to work on 12 projects, each addressing a specific scientific question or technical challenge using available HTAN data
 - Promote access and reuse of HTAN data
 - Promote collaborations to expand the HTAN community
 - Promote development of new methods and tools for HTAN data analysis
 - Identify gaps and limitations of existing HTAN data and resources





November 2024 Data Jamboree Participants

HTAN Associate Membership



- Associate Members are expected to contribute to HTAN by:
 - generating, sharing or analyzing data;
 - jointly developing software or algorithms;
 - developing mutually beneficial resources, protocols or reagents;
 - and/or coordinating development of standards, formats or metadata.
- Applications for Associate Membership require:
 - a letter of support from a current HTAN member;
 - a recent biosketch;
 - a letter of intent from the applicant describing their planned contributions to HTAN.
- Associate Members are encouraged to actively engage in HTAN activities
- Associate Member must abide by all HTAN policies



HTAN Nature Bundle



APRIL 25-30 | AACR.ORG/AACR2025 | #AACR25



Watch accompanying webcast that explored:



Ken S. Lau. PhD



Stanford



Alexia-Ileana Zaromytidou, PhD (Moderator)

Li Ding, PhD, Shannon Hughes, PhD NCI WashU

Vanderbilt

- The history of HTAN
- The goals of assembling cancer atlases
- Functioning of a successful multi-institution consortium
- In numbers: HTAN's scope and scale
- The power of spatial technologies
- Applying evolutionary principles in cancer research
- The importance of understanding the cancer microenvironment
- How you can use HTAN's resources for your own research
- The future of the field



